BOSTON, Oct. 13, 2005 – OptiScan Biomedical Corp., an Alameda, CA-based developer of a glucose monitoring device for hospital use, has raised $36 million in new VC funding. The round was led by NGN Capital and included MedVenture Associates, Morgenthaler Ventures, Ascension Health Ventures, Sanders Morris Harris, The Wellcome Trust and Mitsui & Co., as well as existing stakeholders Prism Venture Partners and EGS Healthcare, both of which reinvested. The company has now raised nearly $70 million in total VC funding since its 1994 inception.
Kingsley Taft, partner, and Danielle Lauzon , associate, of Goodwin Procter represented NGN Capital in this matter.